Laddar populära aktier...
Inledningen av 2024 blev som väntat svag. Marknadsläget är tufft och konsumenten är återhållsam men ...
Över lag kom kvartalet in under Analysguidens prognos, förklarat av en generell konjunkturnedgång.
Redeye concludes that the reported figures mainly were in line with our expectations.
Redeye updates its outlook and fair value range on Lifecare following the company’s Q1 report and an...
Redeye comments on the acquisition announced this morning, where Tobii Dynavox acquires the Australi...
Tar kostnader för åtgärdsplan i kvartalet Omsättningen i kvartalet uppgick till 41,6 mkr, vilket mot...
Blandad kompott i Q1 Nettoomsättningen i Q1(24) ökade med 66% till 12,1 mkr, något under vår förvänt...
Redeye updates on GiG following Q1-results which were lower than expected owing to somewhat softer g...
Redeye initiates coverage of Climeon, providing an attractive waste heat recovery solution generatin...
Redeye maintains a positive view of Transtema despite a weak Q1 and cuts in Base Case and forecasts.
SmartCrafts första kvartal visade på fortsatt bra tillväxt och marginal.
Redeye leave its comments on Xbrane following the announcement of a USD45m deal plus royalties for X...
Redeye gives its preview on OssDsign’s Q1 2024 report, due on May 14.
Etteplan was able to improve its profitability during the first quarter as was expected.
Redeye provides a research update following the Q1 report published by Initiator Pharma earlier toda...